Cohort B: paridiprubart Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Cohort B: paridiprubart comprises 1 peer-reviewed publications across 1 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Acute Lung Injury. Most recent publication: Empowering Respiratory Therapists to Restrict Nebulized 3% Saline and N-Acetylcysteine During Mechanical Ventilation., Respir Care, 2025.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Empowering Respiratory Therapists to Restrict Nebulized 3% Saline and N-Acetylcysteine During Mechanical Ventilation.
    Truwit JD, Fleming K, Nanchal RS, et al. · Respir Care · 2025
    PubMed: PMID 40028879 · NCT06703073 · Acute Lung Injury

Publications by year

20252025: 1 publications.

2025
1

Publications by indication

Acute Lung Injury (1)

  • Empowering Respiratory Therapists to Restrict Nebulized 3% Saline and N-Acetylcysteine During Mechanical Ventilation.
    Respir Care · 2025 · PMID 40028879 · NCT06703073

Publications by journal

All Cohort B: paridiprubart publications (1)

2025 (1 paper)

  1. Empowering Respiratory Therapists to Restrict Nebulized 3% Saline and N-Acetylcysteine During Mechanical Ventilation.
    Truwit JD, Fleming K, Nanchal RS, et al. · Respir Care · 2025 · Derived
    PubMed: PMID 40028879 · NCT06703073 · Acute Lung Injury

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).